Carbamazepine in trigeminal neuralgia: A comparative study with vixotrigine and erenumab in clinical trials
DOI:
https://doi.org/10.33448/rsd-v13i12.47557Keywords:
Trigeminal neuralgia; Carbamazepine; Monoclonal Antibodies; Sodium Channel Blockers.Abstract
Trigeminal Neuralgia (TN) is a chronic neurological condition characterized by recurrent and unilateral episodes of facial pain, with a stabbing, burning or electric shock sensation. The disease interferes with daily activities, resulting in poor quality of life for patients. This study presents a narrative review of the literature, which aims to investigate the efficacy and safety of carbamazepine compared to vixotrigine and erenumab in the treatment of trigeminal neuralgia, based on articles published in the last five years in the main scientific databases, including PubMed, Scielo and Google Scholar. After searching and excluding irrelevant articles, 22 relevant articles were used for the development of the research. TN is one of the most painful and debilitating neurological conditions, with carbamazepine being the first-line treatment, but with long-term side effects. Vixotrigine, a novel sodium channel blocker, has been shown to be effective and well tolerated in clinical trials, while erenumab, an antibody originally developed for migraine, has shown therapeutic potential in patients with refractory TN. This study highlights the need for further clinical research and larger patient populations to assess the efficacy of these new treatments and their integration into clinical practice, expanding the options for the safe and effective management of TN.
References
Araya, E. I., Claudino, R. F., Piovesan, E. J., & Chichorro, J. G. (2020). Trigeminal Neuralgia: Basic and Clinical Aspects. Current neuropharmacology, 18(2), 109–19. https://doi.org/10.2174/1570159X17666191010094350.
Ashina, S., Robertson, C.E., Srikiatkhachorn, A. et al. (2024). Trigeminal neuralgia. Nat Rev Dis Primers, 10, 39. https://doi.org/10.1038/s41572-024-00523-z.
Casarin, S. T. et al. (2020). Tipos de revisão de literatura: considerações das editoras do Journal of Nursing and Health. Journal of Nursing and Health. 10(5). https://periodicos.ufpel.edu.br/index.php/enfermagem/article/view/19924.
Cavalcante, L. T. C. & Oliveira, A. A. S. (2020). Métodos de revisão bibliográfica nos estudos científicos. Psicol. Rev. 26(1). https://doi.org/10.5752/P.1678-9563.2020v26n1p82-100.
Castro, J. B., Naumann, J. C. P., Santos, L. L. dos, Koch, T. B., Naumann, C. H. M., Cavalcanti, A. V. B. de A., Pessoa, G. B. da V., Balestrero, J. G. P., Cavalcanti Filho, J. W. S., Santos, L. A., Alvim, I. F. F., Dantas, E. K. de O., Silva, G. L., & Char, M. H. (2024). Neuralgia do Trigêmeo: desvendando os mistérios da dor facial e avanços terapêuticos. Journal of Social Issues and Health Sciences (JSIHS), 1 (4). https://doi.org/10.5281/zenodo.12819575.
Dunbar, J., Versavel, M., Zhao, Y., Tate, S., Morisset, V., Giblin, G. M. P., Palmer, J., Tidemann-Miller, B., & Naik, H. (2020). Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers. Clinical pharmacology in drug development, 9(1), 62–73. https://doi.org/10.1002/cpdd.739.
Gambeta, E., Chichorro, J. G., & Zamponi, G. W. (2020). Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments. Molecular pain, 16, 1744806920901890. https://doi.org/10.1177/1744806920901890.
Guo, M., Shen, W., Zhou, M., Song, Y., Liu, J., Xiong, W., & Gao, Y. (2024). Safety and efficacy of carbamazepine in the treatment of trigeminal neuralgia: A metanalysis in biomedicine. Mathematical biosciences and engineering : MBE, 21(4), 5335–59. https://doi.org/10.3934/mbe.2024235.
Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders (3ª ed.). Cephalalgia, 38(1), 1–211. https://doi.org/10.1177/0333102417738202.
Katsuki, M., Kawamura, S., Kashiwagi, K., Tachikawa, S., & Koh, A. (2023). Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine. Cureus, 15(3), e35913. https://doi.org/10.7759/cureus.35913.
Khadilkar, S. V., & Patil, V. A. (2021). Medical Management of Trigeminal Neuralgia. Neurology India, 69 (Supplement), S199–S205. https://doi.org/10.4103/0028-3886.315996.
Kotecha, M., Cheshire, W. P., Finnigan, H., Giblin, K., Naik, H., Palmer, J., Tate, S., & Zakrzewska, J. M. (2020). Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia. Journal of pain research, 13, 1601–9. https://doi.org/10.2147/JPR.S247182.
Lambru, G., Zakrzewska, J., & Matharu, M. (2021). Trigeminal neuralgia: a practical guide. Practical neurology, 21(5), 392–402. https://doi.org/10.1136/practneurol-2020-002782.
Li, R., Sun, J., Luo, K., Luo, N., Sun, R., Gao, F., Wang, Y., Xia, Y., Li, X., Chen, L., Ma, R., Shao, X., Liang, Y., & Fang, J. (2024). Electroacupuncture and carbamazepine for patients with trigeminal neuralgia: a randomized, controlled, 2 × 2 factorial trial. Journal of neurology, 271(8), 5122–36. https://doi.org/10.1007/s00415-024-12433-x.
Naderi, Y., Rad, M., Sadatmoosavi, A., Khaleghi, E., Khorrami, Z., Chamani, G., & Shabani, M. (2024). Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review. Clinical and experimental dental research, 10(2), e882. https://doi.org/10.1002/cre2.882.
Parascandolo, E., Levinson, K., Rizzoli, P., & Sharon, R. (2021). Efficacy of Erenumab in the Treatment of Trigeminal Neuralgia: A Retrospective Case Series. Neurology. Clinical practice, 11(3), 227–31. https://doi.org/10.1212/CPJ.0000000000001075.
Radoš I. (2022). Treatment options for trigeminal neuralgia. Acta clinica Croatica, 61(Suppl 2), 96–102. https://doi.org/10.20471/acc.2022.61.s2.12.
Rana, M. H., Khan, A. A. G., Khalid, I., Ishfaq, M., Javali, M. A., Baig, F. A. H., Kota, M. Z., Khader, M. A., Hameed, M. S., Shaik, S., & Das, G. (2023). Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review. Biomedicines, 11(10), 2606. https://doi.org/10.3390/biomedicines11102606.
Romero, J. G. de A. J., Pedras, R. B. de N., & Almeida-Leite, C. M. (2020). Botulinum toxin in pain management of trigeminal neuralgia: literature review. Brjp, 3(4), 366–73. https://doi.org/10.5935/2595-0118.20200185.
Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta Paul. Enferm. 20(2). https://doi.org/10.1590/S0103-21002007000200001.
Schlereth, T. (2020). Guideline "diagnosis and non interventional therapy of neuropathic pain" of the German Society of Neurology. Neurological research and practice, 2, 16. https://doi.org/10.1186/s42466-020-00063-3.
Schott Andersen, A. S., Maarbjerg, S., Noory, N., Heinskou, T. B., Forman, J. L., Cruccu, G., Ashina, M., & Bendtsen, L. (2022). Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark. The Lancet. Neurology, 21(11), 994–1003. https://doi.org/10.1016/S1474-4422(22)00294-0.
Szok, D., Tajti, J., Nyári, A., & Vécsei, L. (2019). Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behavioural neurology, 2019, 8685954. https://doi.org/10.1155/2019/8685954
Veerapaneni, K. D., Kapoor, N., Veerapaneni, P., Lui, F., & Nalleballe, K. (2024). Trigeminal Neuropathy. In StatPearls. StatPearls Publishing.
Witty, D. R., Alvaro, G., Derjean, D., Giblin, G. M. P., Gunn, K., Large, C., Macpherson, D. T., Morisset, V., Owen, D., Palmer, J., Rugiero, F., Tate, S., Hinckley, C. A., & Naik, H. (2020). Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia. ACS medicinal chemistry letters, 11(9), 1678–87. https://doi.org/10.1021/acsmedchemlett.0c00263.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Giulia Lagareiro Sasanovycz; Izabella Soares Moreno; Rafaela Giraçol; Rita Heloísa da Costa Yoem; Raquel Silveira Bertoluci
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
